NVNBW Form 144 Notice — 9,800 Common Shares Scheduled for 09/15/2025

Rhea-AI Filing Summary

enVVeno Medical Corp (NVNBW) filed a Form 144 notice reporting a proposed sale of 9,800 shares of common stock, acquired in an open market purchase on 12/31/2024. The filing lists the aggregate market value of the shares to be sold as $8,143.00 and shows 19,247,141 shares outstanding. The approximate date of sale is stated as 09/15/2025 and the broker named is The Charles Schwab Corporation, with the trade to occur on NASDAQ. The filer certifies they are not aware of any undisclosed material adverse information and indicates no securities were sold by the filer in the past three months.

Insights

Securities Analyst

TL;DR: Routine Form 144 notice for a small open-market sale of 9,800 shares, scheduled for September 15, 2025.

The filing documents a proposed sale under Rule 144 of 9,800 shares of common stock acquired on 12/31/2024 via open-market purchase. The transaction is routed through The Charles Schwab Corporation and is scheduled for 09/15/2025 on NASDAQ. The reported aggregate market value is $8,143 versus total shares outstanding of 19,247,141, indicating the notice covers a very small fraction of the company’s capitalization. The filer affirms no undisclosed material adverse information and reports no sales in the prior three months. This appears to be a routine disclosure required when restricted or control securities are proposed to be sold.

Compliance/Risk Analyst

TL;DR: Compliance check: filing contains required declarations and broker details; no red flags within provided data.

The Form 144 includes core compliance elements: filer and issuer identifiers, acquisition date and method, broker name and address, number of shares, aggregate value, outstanding shares, and planned sale date. The filer represents no knowledge of undisclosed material adverse information and reports no recent sales. Based on the provided content, the filing satisfies the notice requirements for a proposed Rule 144 sale absent further contextual facts.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	THE CHARLES SCHWAB CORPORATION 3000 Schwab Way Westlake TX 76262	9800	8143.00	19247141	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	12/31/2024	OPEN MARKET PURCHASE	OPEN MARKET			9800	12/31/2024	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does enVVeno Medical Corp's Form 144 (NVNBW) report?

The Form 144 reports a proposed sale of 9,800 common shares acquired on 12/31/2024 via open market purchase, with an aggregate market value of $8,143.00.

When is the approximate date of the proposed sale on the Form 144?

The filing lists the approximate date of sale as 09/15/2025.

Which broker is named for the proposed sale in the Form 144?

The broker named is The Charles Schwab Corporation, located at 3000 Schwab Way, Westlake, TX 76262.

How many enVVeno shares are outstanding according to the filing?

The Form 144 shows 19,247,141 shares outstanding.

Did the filer report any securities sold in the past three months?

The filing states Nothing to Report for securities sold during the past three months.